Navigation Links
Dyadic International Reports Q2 2014 Financial Results
Date:8/14/2014

uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements in this earnings press release. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this earnings press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Six Months Ended June 30,  Three Months Ended June 30, 2014201320142013Revenue: (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) Product Relat
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Dyadic And CIMV Enter Into Collaboration To Commercialize Second Generation Biofuel Technology
2. Thomas Dubinski joins Dyadic as Chief Financial Officer
3. Dyadic International To Present At Two Major Conferences In December 2013
4. Dyadic International Reports Third Quarter 2013 Financial Results
5. Dyadic International To Announce Third Quarter 2013 Financial Results And Host Conference Call On Thursday, November 14, 2013
6. Dyadic International Reports Second Quarter 2013 Financial Results
7. Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech
8. Dyadic International Reports First Quarter 2013 Financial Results
9. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
10. Danai Brooks Joins Dyadic International as Chief Operating Officer
11. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience ... human vision system, announced today a partnership with eight-time All-Star, ... Paul to develop a new mobile app designed for ... real-life on-court performance. Vision is the inception of ... a ball or blocking a pass. The critical impact vision ...
(Date:8/26/2015)... Manhattan, KS (PRWEB) , ... August 26, 2015 ... ... & Biologic Solutions, announces today that a second US laboratory is to open ... in accordance with the continued partnership and long-term growth of research and development ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Calif., Feb. 2 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group ... Conference held in Naples, FL. , , ... Speaker: ... Date: ...
... SAN DIEGO, Feb. 2 BioMed Realty Trust, Inc. (NYSE: ... for its fourth quarter and year ended December 31, 2008 ... D. Gold, Chairman and Chief Executive Officer, and Kent Griffin, ... call at 10:00 a.m. Pacific Time on Thursday, February 12, ...
... Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures ... acquisition of all the technology and intellectual property for ... for application in three gastrointestinal cancers. Cancer Advances was ... to acquire products developed to inhibit the hormone, gastrin, ...
Cached Biology Technology:IPC The Hospitalist Company, Inc. to Present at Deutsche Bank 2009 Small and Mid Cap Conference 2BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results 2Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers 2Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers 3
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... When forest biologist Claire Williams boards ferries bound for North ... coast, ferry captains call her the "Pollen Lady." ... forth from the islands to the mainland, collecting pine pollen ... from the loblolly pine the most commonly planted tree ...
... are often hamstrung by less-than-ideal grafting material when performing ... or cancer. Conventional synthetic bone grafts are typically made ... conform to the complex and irregular shapes that often ... fixation devices that require open surgeries to insert and ...
... -- Highly dangerous Cryptococcus fungi love sugar and ... particular, they thrive on a sugar called inositol ... To borrow inositol from a person,s brain, the fungi ... transporter molecules. While a typical fungus has just two such ...
Cached Biology News:Gone with the wind: Far-flung pine pollen still potent miles from the tree 2Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2This is your brain on Cryptococcus: Pathogenic fungus loves your brain sugar 2
... Studio Enterprise is integrated informatics solution ... mechanisms and drug response modeling. This ... worlds largest knowledge base of biological ... MedScan module capable of extracting pathway-related ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... Preparation Note: Prepared by a modification ... et al., Biotechnol. Bioeng., ... One unit will yield an A ... ml of water (1 cm light ...
Biology Products: